Vagus Nerve Stimulation for POTS and Dysautonomia: What the Research Shows

Introduction: One Promising Trial, Held in Proportion

Postural orthostatic tachycardia syndrome (POTS) is a form of dysautonomia — a disorder of the autonomic nervous system — in which standing up triggers an excessive rise in heart rate, often with light-headedness, palpitations, fatigue, and brain fog. It disproportionately affects younger women, and effective treatments are limited, which has driven interest in new approaches. Vagus nerve stimulation (VNS) is one of them, and there is now a single small randomised trial to discuss rather than mechanism alone.

This article looks at that evidence honestly. The result is encouraging — a sham-controlled trial found a measurable benefit — but it is one small study, and one study, however well designed, is a starting point rather than a conclusion.

What Is POTS and Dysautonomia?

The autonomic nervous system controls the body's automatic functions — heart rate, blood pressure, digestion, temperature — through a balance between its sympathetic ("fight or flight") and parasympathetic ("rest and digest") branches. In POTS, that balance is disturbed: on standing, heart rate climbs abnormally (by at least 30 beats per minute in adults, or to over 120 beats per minute) without a large drop in blood pressure. The result is a cluster of disabling symptoms that worsen upright.

POTS often overlaps with other autonomic and post-viral conditions, and its mechanisms vary between patients — which is part of why it is difficult to treat and why a single intervention is unlikely to suit everyone. Standard management relies on non-drug measures — increased fluid and salt intake, compression garments, and graded exercise — alongside selected medications, none of which is curative; that gap is what motivates interest in new approaches such as vagal stimulation.

The Rationale: Vagal Tone and Autonomic Balance

The reasoning behind VNS for POTS is intuitive. If the disorder reflects too much sympathetic drive and too little parasympathetic (vagal) restraint, then boosting vagal activity might help rebalance the system. The vagus nerve is the principal parasympathetic pathway, and its influence on heart-rate regulation is well established and often indexed by heart rate variability (HRV).

There is, however, an important caveat at the foundation of this rationale. It assumes that non-invasive taVNS reliably increases vagal tone — and that assumption is not well established. A 2026 systematic review of neuromodulation and HRV found that transcutaneous VNS produced no consistent, significant effect on HRV across randomised trials (Souza et al., 2026). So while the clinical trial below measured real changes in postural heart rate, the broader question of how dependably taVNS shifts autonomic balance remains open. A treatment can show an effect in one trial while the mechanism behind it is still being worked out.

Stavrakis 2024: The Key Trial

The central piece of evidence is Stavrakis et al. (2024), published in JACC: Clinical Electrophysiology. This was a randomised, sham-controlled trial of non-invasive (tragus) vagus nerve stimulation in 26 patients with POTS — 12 receiving active stimulation and 14 sham — over two months.

The primary finding favoured active stimulation: the rise in heart rate on standing was significantly smaller in the active group than the sham group — a mean postural heart-rate increase of 17.6 beats per minute versus 31.7 beats per minute (P = 0.01). The active group also showed reductions in certain autoantibodies and inflammatory markers, and no device-related side effects were observed.

This is a clean, positive result from a properly controlled design, which is exactly what gives it value. But its limits are equally clear:

The trial enrolled just 26 participants at a single centre, and the cohort was entirely female. A result this small and this specific is a strong hint, not a settled conclusion. It needs replication in larger, more diverse populations before vagus nerve stimulation could be considered an established POTS therapy.

POTS After COVID-19

Interest in this area has been amplified by the pandemic. Autonomic dysfunction is one of the most consistently reported features of long COVID: in a global survey of 2,314 affected adults, around two-thirds had questionnaire scores indicating moderate-to-severe autonomic dysfunction, and POTS was the most common associated diagnosis (Larsen et al., 2022). That has brought a large new group of people with post-viral dysautonomia — and renewed attention to whether vagal interventions might help them.

It is worth being careful here, though. The Stavrakis trial studied POTS broadly, not post-COVID POTS specifically, and the evidence for VNS in post-viral autonomic dysfunction is weaker still. We discuss that separately in our article on VNS for long COVID, where the best controlled trials have so far been disappointing. Encouraging POTS data and disappointing long-COVID-fatigue data can coexist, and conflating them would mislead in both directions.

How Strong Is the Evidence?

Honestly assessed, the evidence for VNS in POTS is a single small but positive sham-controlled trial, supported by a coherent (if not fully proven) autonomic rationale. That places it among the more promising of the emerging applications — better than a collection of uncontrolled pilots — but well short of established. One trial cannot tell us how large or durable the effect is, who responds best, or whether it generalises beyond the specific population studied.

What One Small Trial Can and Cannot Tell Us

A single positive trial is genuinely encouraging, but it is worth being clear about how much weight 26 participants can bear. The Stavrakis result tells us that, in this specific group, active stimulation reduced the postural heart-rate rise more than sham over two months — a real, controlled effect. It also hinted at a mechanism, with reductions in certain autoantibodies and inflammatory markers that fit the idea of an immune and autonomic contribution to POTS.

What it cannot tell us is almost everything else a patient would want to know. It cannot establish how large the benefit is in the broader POTS population, which includes men, older patients, and the several recognised subtypes that differ in their underlying physiology — the trial was conducted entirely in women at one centre. It cannot tell us whether symptoms, not just heart-rate numbers, improve in a way that changes daily life, nor how long any benefit lasts, nor whether it holds once stimulation stops. And because POTS is so heterogeneous, a result in one cohort may not transfer to another.

This is the normal, healthy state of an early finding: a clean positive signal that earns the right to a larger, more diverse, and longer trial — not a conclusion that the question is answered.

A Condition That Resists One-Size-Fits-All Treatment

One reason to be cautious about extrapolating from a single POTS trial is that POTS is not a single disease. Clinicians recognise several overlapping subtypes that differ in their underlying mechanism: a hyperadrenergic form driven by excess sympathetic activity; a neuropathic form involving partial loss of peripheral nerve function and blood pooling in the legs; and a hypovolaemic form linked to low blood volume. Many patients show features of more than one.

This heterogeneity has direct consequences for how a treatment is likely to behave. An intervention aimed at shifting autonomic balance toward parasympathetic activity might plausibly help one subtype more than another, and a trial enrolling a particular mix of patients may not predict the result in a different mix. It is part of why POTS has proved difficult to treat in general, and why no single therapy has emerged as broadly effective.

For vagus nerve stimulation specifically, it means the encouraging Stavrakis result — obtained in a relatively uniform group of women at one centre — cannot be assumed to generalise across the full clinical spectrum of POTS. A treatment that works for one subtype could be diluted to nothing when tested across all of them, or could prove especially useful in a subgroup that a broad trial would obscure. Sorting this out requires larger studies designed to examine subtypes, not just averages.

Safety

Non-invasive tragus and auricular VNS are generally well tolerated, with mostly mild and transient effects and, in the Stavrakis trial, no device-related adverse events — consistent with the broader safety profile of VNS. As with every application, good tolerability does not establish effectiveness.

The Bottom Line

For POTS and dysautonomia, vagus nerve stimulation is a promising idea backed by one encouraging trial:

- The autonomic rationale is coherent, though the premise that taVNS reliably raises vagal tone is itself unproven (Souza et al., 2026).
- A small, sham-controlled trial found that non-invasive VNS reduced postural tachycardia versus sham (Stavrakis et al., 2024).
- The evidence is limited to a single small, single-centre, all-female study and awaits replication.
- Post-COVID dysautonomia has driven much of the interest, but VNS evidence in that specific group is weaker (Larsen et al., 2022).

If you live with POTS and are considering vagus nerve stimulation, the reasonable view is hopeful but cautious: there is one good trial pointing in a positive direction, not a body of proof. Discuss it with a clinician familiar with autonomic disorders rather than self-treating, and browse the underlying studies in our Evidence Database.

---

References

Larsen, N.W. et al. (2022). Characterization of autonomic symptom burden in long COVID: a global survey of 2,314 adults. Frontiers in Neurology, 13, 1012668.

Souza, R. et al. (2026). Neuromodulation of heart rate variability: a systematic review. Autonomic Neuroscience, 263, 103379.

Stavrakis, S. et al. (2024). Noninvasive vagus nerve stimulation in postural tachycardia syndrome: a randomized clinical trial. JACC: Clinical Electrophysiology, 10(2), 346–355.